Lenalidomide reduced in a dose-dependent manner IRF4 expression (measured by flow cytometry) in OPM2 myeloma cells (60% reduction with 10 μg/ml lenalidomide, Figure 7E and Supplementary Figure S7). This evidence concerns the gene IRF4 and plasma cell myeloma.